Daily Anesthesiology Research Analysis
Three anesthesia-relevant studies stand out today: a randomized placebo-controlled trial shows 16 mg oral dexamethasone meaningfully reduces early postoperative pain after total knee arthroplasty; a British Journal of Anaesthesia human volunteer study links dexmedetomidine-induced disconnected consciousness to reduced thalamus-driven cortical synchrony; and a network meta-analysis across 52 RCTs identifies 0.4 mg/kg ciprofol as an optimal endoscopy sedative dose with fewer cardiopulmonary advers
Summary
Three anesthesia-relevant studies stand out today: a randomized placebo-controlled trial shows 16 mg oral dexamethasone meaningfully reduces early postoperative pain after total knee arthroplasty; a British Journal of Anaesthesia human volunteer study links dexmedetomidine-induced disconnected consciousness to reduced thalamus-driven cortical synchrony; and a network meta-analysis across 52 RCTs identifies 0.4 mg/kg ciprofol as an optimal endoscopy sedative dose with fewer cardiopulmonary adverse events than propofol.
Research Themes
- Perioperative analgesia optimization with oral corticosteroids
- Consciousness mechanisms under sedation and thalamocortical synchrony
- Sedation pharmacology and dose optimization for endoscopy
Selected Articles
1. Oral Corticosteroids Reduce Pain After Total Knee Arthroplasty: A Higher Dose of Dexamethasone Effectively Controlled Pain During Motion: A Dose-Response Randomized Placebo-Controlled Trial.
In a randomized placebo-controlled trial of 120 TKA patients, oral dexamethasone reduced early postoperative pain. Both 8 mg and 16 mg decreased pain at rest within 48 hours, but only 16 mg significantly reduced pain during motion, achieving roughly a 50% reduction versus placebo at 48 hours.
Impact: The study delivers Level I evidence for a practical, scalable analgesic strategy using oral dexamethasone with a clear dose-response, directly informing multimodal perioperative pain protocols.
Clinical Implications: Consider adding oral dexamethasone 16 mg daily (pre-op and postoperative days 1–4) to multimodal analgesia for TKA to improve early pain control, with attention to glucocorticoid contraindications and monitoring for adverse effects.
Key Findings
- Oral dexamethasone 16 mg significantly reduced pain during motion at 48 hours versus placebo (about 50% reduction; p = 0.006).
- Both 8 mg and 16 mg reduced pain at rest within 48 hours compared with placebo (p < 0.05).
- Once-daily dosing starting preoperatively and continued through postoperative day 4 was effective in the early postoperative period.
Methodological Strengths
- Randomized, placebo-controlled design with predefined dose-response comparison
- Use of linear mixed-effects modeling to assess longitudinal pain outcomes
Limitations
- Single-country, single-surgery context may limit generalizability beyond TKA and non-Thai populations
- Short observation window (48 hours) with limited safety assessment of steroid-related adverse events
Future Directions: Evaluate safety and efficacy across broader surgical populations, compare with intravenous corticosteroids, and assess functional recovery and opioid-sparing effects over longer horizons.
BACKGROUND: Intravenous corticosteroids have been used to manage pain following total knee arthroplasty (TKA). Oral dexamethasone has good bioavailability and is suitable for ambulatory TKA. This study investigated the efficacy and dose-response relationship of oral dexamethasone in pain control after TKA. METHODS: In this randomized controlled trial, 120 Thai patients (mean, 68 ± 8 years; 86% female) undergoing primary TKA were allocated to 1 of 3 groups: 16 mg of oral dexamethasone (DEX-16), 8 mg of oral dexamethasone (DEX-8), or placebo. Dexamethasone or placebo was administered once daily, in the morning before surgery and the morning of the first 4 postoperative days. The primary outcome was pain at rest and during motion, measured over time. Linear mixed-effects modeling was used to compare outcomes between groups. RESULTS: Both DEX-8 and DEX-16 significantly reduced pain at rest within 48 hours postoperatively compared with placebo (p < 0.05). However, only DEX-16 significantly reduced pain during motion (p < 0.05). At 48 hours postoperatively, the DEX-16 group showed approximately 50% reductions in pain at rest (p < 0.001) and during motion (p = 0.006) relative to placebo. CONCLUSIONS: Oral dexamethasone was effective in reducing pain after TKA, with a 16-mg dose providing superior pain relief during motion, compared with an 8-mg dose, within the first 48 hours. These findings support the use of oral dexamethasone as part of multimodal pain management, particularly in an ambulatory TKA setting. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
2. Thalamic contributions to predictive coding and disconnected consciousness in human volunteers.
Using an auditory oddball paradigm with EEG in 18 volunteers, surprise-related cortical synchrony was robust in wakefulness but blunted under dexmedetomidine-induced disconnected consciousness. Source-level coactivation correlated with surprise while awake but not during disconnection, implicating higher-order thalamic mechanisms in sensory disconnection.
Impact: This mechanistic human study advances understanding of anesthesia-induced disconnection by linking predictive coding to thalamocortical synchrony, informing monitoring strategies and theoretical models of consciousness under sedation.
Clinical Implications: Insights into thalamocortical synchrony under dexmedetomidine may guide development of EEG-based markers for depth of sedation and inform strategies to avoid unintended disconnection during procedural sedation.
Key Findings
- Surprise (prediction error) was strongly coupled to frontal–posterior EEG responses during wakefulness but not during dexmedetomidine-induced disconnection.
- Source-reconstructed voxel coactivation was higher in wakefulness and scaled with surprise; this relationship was abolished in the disconnected state.
- Findings support a model where impaired higher-order thalamic synchronization leads to sensory disconnection under sedation.
Methodological Strengths
- Within-subject comparison across wakefulness and pharmacologically induced disconnection with serial awakening confirmation
- Integration of computational modeling of surprise with source-reconstructed EEG and cluster-based statistics
Limitations
- Small sample size (n=18) limits generalizability and statistical power
- Single sedative agent (dexmedetomidine) and EEG modality may not capture broader anesthetic states
Future Directions: Extend to other anesthetics and multimodal neuroimaging, and evaluate EEG-based synchrony metrics as real-time sedation depth indicators linked to patient experience.
BACKGROUND: We can be conscious without awareness of the external world, as when dreaming, a state of disconnected consciousness. The higher-order thalamus is proposed to direct conscious experience to relevant external events through synchronising cortical activity. While disconnected, even surprising external sensory information is ignored. We hypothesise that in wakefulness the cortex synchronises in response to surprise and that this effect is reduced in states of disconnection. METHODS: An auditory oddball paradigm, with EEG recording, was presented to 18 volunteer subjects while either awake, or disconnected under dexmedetomidine sedation, as confirmed using serial awakening. A computational model of surprise (prediction error) was fit to the auditory tone sequence and cluster-based analysis compared responses across states. Voxel coactivation (synchronisation) was calculated from source-reconstructed data. RESULTS: Surprise was more strongly associated with awake EEG data compared with disconnection. In wakefulness, a significant negative regression coefficient occurred from 33 to 356 ms after the tone over frontal regions (P<0.001), whereas posteriorly a positive coefficient occurred from 37 to 400 ms (P<0.001). This effect was diminished in disconnection. Coactivation of voxels was stronger while awake, and significantly associated with level of surprise. This was perturbed in disconnection (P<0.001), showing reduced synchrony in the disconnected state with no impact of surprise. CONCLUSIONS: These findings support the proposal that disconnection emerges from loss of cortical synchronisation in proportion to the salience of sensory stimuli. Impairment of higher-order thalamic synchronisation of cortical activity might underlie sensory disconnection. CLINICAL TRIAL REGISTRATION: NCT03284307.
3. Optimal dosing of ciprofol for gastrointestinal endoscopy: a systematic review and network meta-analysis.
Across 52 RCTs (n=7,283), ciprofol was associated with fewer injection pain and cardiopulmonary adverse events than propofol. Network estimates suggest 0.4 mg/kg ciprofol optimally balances efficacy and safety for endoscopic sedation.
Impact: This comprehensive synthesis provides dose-specific guidance for a new sedative agent, directly informing procedural sedation protocols and safety optimization.
Clinical Implications: For gastrointestinal endoscopy sedation, consider ciprofol 0.4 mg/kg to reduce injection pain, respiratory depression, and hypotension relative to propofol, while acknowledging limited non-Chinese data and the need for local validation.
Key Findings
- Ciprofol reduced injection pain, respiratory depression, bradycardia, and hypotension compared with propofol across 52 RCTs.
- Ciprofol 0.4 mg/kg vs propofol 2 mg/kg: injection pain RR 0.13 (95% CrI 0.08–0.21), respiratory depression RR 0.36 (0.26–0.48), hypotension RR 0.62 (0.44–0.84).
- Evidence confidence graded high for injection pain and respiratory depression, moderate for hypotension; generalizability limited by predominantly Chinese populations.
Methodological Strengths
- PRISMA-guided systematic review and network meta-analysis integrating 52 randomized trials
- Dose-level comparisons with GRADE assessment of confidence
Limitations
- Predominance of Chinese populations limits external validity to other regions and healthcare settings
- Heterogeneity in procedural protocols and outcome definitions across trials
Future Directions: Conduct multicountry RCTs to validate 0.4 mg/kg dosing across diverse populations and procedures, including head-to-head comparisons with propofol on recovery profiles and patient-reported outcomes.
BACKGROUND: The use of ciprofol for endoscopic sedation is relatively recent; however, no definitive conclusions have been drawn regarding its optimal dose. This study evaluated the optimal ciprofol dose for sedated endoscopy using a network meta-analysis. METHODS: PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang, VIP Chinese scientific and technological journal full-text database, and SinoMed were searched from inception to July 2025. The review incorporated all available comparative trials assessing ciprofol versus propofol for endoscopic sedation. The primary outcome was the incidence of injection pain and adverse cardiopulmonary reactions. RESULTS: A total of 52 randomized controlled trials (RCTs) involving 7283 patients were included. Ciprofol demonstrated a significantly lower incidence of injection pain, respiratory depression, bradycardia, and hypotension compared to propofol. Compared with propofol 2 mg/kg, ciprofol 0.4 mg/kg were associated with a significantly lower incidence of injection pain (RR[95%CrI] = 0.13[0.08, 0.21], high confidence), respiratory depression (RR[95%CrI] = 0.36[0.26, 0.48], high confidence), and hypotension (RR[95%CrI] = 0.62[0.44, 0.84], moderate confidence). CONCLUSION: A dose of 0.4 mg/kg of ciprofol may represent the optimal dose for endoscopic sedation, as it can reduce the incidence of injection pain, respiratory depression, and hypotension. However, most included studies focus on Chinese populations, which limits the global applicability of the findings. Future RCTs conducted in more countries are warranted.